Moleculin Completes Dosing Patients in Part A of Pivotal MIRACLE Trial; Comprehensive Data Readout on Track for Q1 2027

What happened

Moleculin Biotech said dosing is complete in Part A of its pivotal Phase 2/3 MIRACLE trial. The trial tests Annamycin with cytarabine in adults with relapsed or refractory acute myeloid leukemia. Full Part A data from the 90-patient group is expected in the first quarter of 2027.

Confirmed

Global impact / market context

Completing treatment in this 90-patient group moves the company closer to choosing an Annamycin dose for Part B. The first-quarter 2027 data should show how the drug combination performs in patients who failed different first-line treatments, which shapes the trial's next stage.

Analyst inference

Investors in this small drug developer face a wait until early 2027 for the key result. Until then, spending on the trial continues without new revenue, so the readout and dose choice are the main events that could change views on the company's prospects.

Analyst inference

What to watch

1. The company remains on track to report comprehensive Part A data in the first quarter of 2027, after completing dosing in the 90-patient randomized, double-blind group. Confirmed
2. The planned data should support selection of the best Annamycin dose to move into Part B, so watch whether the company confirms that a dose is chosen. Proposed
3. Watch results in patients who failed 7+3 chemotherapy or venetoclax-based regimens, since balanced data across these groups would support the drug's use in hard-to-treat leukemia. Analyst inference

Evidence

• globenewswire.com